Effect of Niaspan on Cholesterol in Men
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00765284 |
Recruitment Status
:
Completed
First Posted
: October 2, 2008
Last Update Posted
: June 30, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To determine whether 8 weeks of Niaspan treatment increases cholesterol efflux in male subjects with low HDL-C cholesterol when compared to no treatment.
To determine whether 8 weeks of Niaspan treatment increases fecal cholesterol excretion when compared to no treatment.
To determine whether 8 weeks of Niaspan treatment increases the rate of global reverse cholesterol transport when compared to no treatment.
Condition or disease |
---|
HDL Cholesterol |
Study Type : | Observational |
Estimated Enrollment : | 15 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Effect of Niaspan on Parameters of Reverse Cholesterol Transport and HDL-C Subclasses in Male Subjects With Low HDL-C Levels |
Study Start Date : | December 2007 |
Actual Primary Completion Date : | June 2011 |
Actual Study Completion Date : | June 2011 |

Group/Cohort |
---|
Treatment
Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
|
Placebo
Five subjects will be low HDL-C male volunteers who will receive only aspirin.
|
- To determine whether 8 weeks of Niaspan treatment increases the following: cholesterol efflux, fecal cholesterol excretion, and the rate of global reverse cholesterol transport, in male subjects with low HDL-C cholesterol when compared to no treatment. [ Time Frame: 8 weeks ]
- To measure the longitudinal effects of 8 weeks of Niaspan treatment on percent change in concentration of specific HDL-C sub-fractions when compared to no treatment. [ Time Frame: 8 weeks ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
Subjects meeting the following criteria at the Screening Visit will be eligible to participate:
- Provide written informed consent
- Male
- Age 18 to 70 years
- BMI 18.5-40 kg/m2
- HDL-C values <40 mg/dL
- Triglyceride value 150-500 mg/dL.
- Good health based on medical history, physical examination and laboratory safety tests performed at the screening visit or prior to initial dose of study medication.
- No clinically significant abnormality on ECG performed at the screening visit or prior to initial dose of study medication.
- Non-smoker and no other use of nicotine containing products for at least 6 months and does not plan to begin smoking during the course of the study.
- Dietary or nutritional remedies including plant sterol containing products (i.e. Benecol, SmartBalance, etc) of any sort for at least 2 weeks prior to and throughout the study.
- Willing to avoid the use of lipid modifying medications (excluding statins) such as the fibrates, cholestyramine, fish oil, and ezetimibe within 8 weeks prior to and during the study.
- Avoidance of extreme change of physical activity from screening through the follow-up period.
Exclusion Criteria:
Subjects are excluded from participation in the study if any of the following criteria apply:
- History of intolerance to Niacin or Niaspan.
- Treatment with Niacin or Niaspan in the past 3 months (Multivitamin use with non-pharmacologic doses of Niacin - less than 500mg per day - is allowed).
- History of stroke, chronic seizures, or major neurological disorder.
- Significant emotional problems or a history of clinically significant psychiatric disorder.
- Bleeding diathesis or intolerance to aspirin.
- Anemia as defined as a hematocrit < 25%.
- History of gastritis, bleeding gastric or duodenal ulcers.
- History Type 1 or Type 2 diabetes, or fasting plasma glucose >125 mg/dL at screening or 75 gm OGTT with 2 hour glucose >140mg/dL.
- History of illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk through participation.
- History of ileal bypass, gastric bypass, or other condition associated with malabsorption.
- Abnormal thyroid function tests.
- AST or ALT > 1.5x the upper limit of normal.
- Active or recent gastrointestinal condition such as gastroenteritis, irritable bowel syndrome, chronic constipation, or diarrhea which may affect bowel movements.
- History of plant sterol storage disease or a history of intolerance to plant sterols or plant sterol containing products.
- History of neoplastic disease (i.e. leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment. Exceptions include adequately treated non-melanomatous skin carcinoma, and other malignancies that may have been treated successfully >10 years prior to the screening visit with no evidence of recurrence.
- Excessive alcohol consumption defined as > three glasses of alcoholic beverages or distilled spirits per day. *** Must avoid excessive alcohol consumption throughout study.
- Currently using psyllium or other fiber based laxatives, phytosterol margarines, and/or over the counter (OTC) treatments that are known to affect serum lipids and has NOT been treated with a stable regimen for > 6 weeks prior to screening (Visit 1) or the subject DOES NOT agree to continue this regimen for the duration of the clinical trial.
- Regular user of illicit drugs or history of drug abuse (including alcohol) within the previous 2 years.
- Use of anabolic agents.
- Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject
- Use of any investigational drug within 30 days before screening

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00765284
United States, Texas | |
Diabetes and Glandular Research Associates | |
San Antonio, Texas, United States, 78229 |
Study Director: | Scott Turner, PhD | KineMed, Inc. |
Responsible Party: | Drina Boban/ Clinical Studies Director, KineMed, Inc. |
ClinicalTrials.gov Identifier: | NCT00765284 History of Changes |
Other Study ID Numbers: |
KM-12 |
First Posted: | October 2, 2008 Key Record Dates |
Last Update Posted: | June 30, 2011 |
Last Verified: | June 2011 |
Keywords provided by KineMed:
HDL RCT Cholesterol |
Additional relevant MeSH terms:
Niacin Nicotinic Acids Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |
Vasodilator Agents Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs |